Pallas Health vs Enhance MD: Clinician Choice or Lowest Intro Price
Quick verdict: Pallas Health vs Enhance MD
Pallas Health gives a clinician the option to prescribe FDA-approved brand-name GLP-1s or US-compounded semaglutide with compounded semaglutide priced at $139 first month then $199/mo average; Enhance MD emphasizes the lowest first-month rates, with semaglutide starting at $49 first month and flat-rate pricing thereafter. Early verdict: choose Pallas when you want clinician access to brand-name pens or compounded options in one intake; choose Enhance MD when a very low first-month price and flat-rate dosing matter most.
Start Pallas intake and see brand or compounded options
How they differ at a glance
This comparison focuses on the most distinctive, supported differences: starting price and introductory offers, pricing model and dose escalation, availability of branded products versus only compounding, clinician review and care inclusion, and regulatory notes about compounded medications. The primary keyword appears as part of this head-to-head: Pallas Health vs Enhance MD.
Starting price and introductory cost
Pallas Health lists compounded semaglutide at $139 for the first month, with subsequent renewal structured as $597 every 12 weeks, which the provider reports as a $199/month average. Enhance MD advertises semaglutide from $49 for the first month and tirzepatide from $99 for the first month. These are the verified first-month figures captured on each provider’s pages.
See Enhance MD first-month semaglutide pricing
Pricing model and dose escalation
Pallas prices its compounded plans by medication rather than by milligram, so Pallas states that titrating up does not raise the plan price; compounded semaglutide renews every 12 weeks at the stated plan rate. Enhance MD emphasizes flat-rate pricing: the same price at every dose with no fee escalation during titration. Both providers are direct-pay and do not bill insurance according to the supplied facts.
Brand-name availability versus compounded-only options
Pallas Health offers FDA-approved brand-name products including Wegovy, Ozempic, Zepbound and Mounjaro alongside clinician-personalized compounded semaglutide or tirzepatide when a brand medication is not the right fit. Enhance MD, as captured, offers compounded semaglutide and tirzepatide only and does not list branded pens. If access to branded, FDA-approved pills or pens is an explicit goal, only Pallas reports offering brand-name options as part of its intake.
Clinician review, care and platform features
Pallas describes a US-licensed clinician who reviews your health history and personalizes the plan; Pallas also includes provider care, ongoing check-ins and care-team messaging inside the plan price and notes no membership fee. Enhance MD describes clinician-directed compounds and highlights treating more than 10,000 patients; the site emphasizes clinician oversight and flat-rate pricing but captured materials do not list the exact care-inclusion details in the same terms as Pallas.
Begin Pallas intake for clinician review and included care
Regulatory note and compounding disclosures
Both providers include the regulatory clarification that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Pallas explicitly adds that it does not manufacture or compound medication and that compounded medications are prepared by US-licensed compounding pharmacies and “the medication you receive may differ in appearance from any product shown.” Enhance MD likewise states that its compounded medications are not FDA-approved finished products.
| Criterion | Pallas Health | Enhance MD |
|---|---|---|
| Starting price – semaglutide | $139 first month; then $597 every 12 weeks ($199/mo avg) | $49 first month |
| Pricing model | Compounded plans priced by medication, intro month then 12-week renewals | Flat-rate pricing – same price at every dose after intro |
| Brand vs compounded | Offers FDA-approved Wegovy, Ozempic, Zepbound, Mounjaro and compounded options | Compounded semaglutide and tirzepatide only |
| Care included | Provider care, check-ins and messaging included in plan price; no membership fee | Clinician-directed care; site highlights treated volume but care-inclusion details not identically stated |
| Regulatory note | Compounded meds are not FDA-approved; prepared by US-licensed compounding pharmacies | Compounded meds are not FDA-approved finished products |
| Shipping | Free expedited and discreet shipping reported | Shipping details captured but not summarized as free expedited on the captured evidence |
Other practical differences to weigh
Pallas notes asynchronous, 100% online care in most states and a video visit requirement in seven states plus Washington, D.C. Pallas also lists care-team hours and the ability to self-serve refills and plan changes. Enhance MD promotes high patient volume and transparent flat-rate pricing as a budget advantage in early months. The supplied facts do not include additional outcome, efficacy or insurance-billing claims beyond what is quoted above.
Check Enhance MD flat-rate and first-month offers
Compare Pallas plan details and brand options
Conclusion: Pallas Health vs Enhance MD
Summing up the documented differences: Pallas Health combines clinician access to branded, FDA-approved GLP-1s and US-compounded options in one intake, with a compounded semaglutide first month at $139 and plan renewals that average $199/mo; Enhance MD emphasizes the lowest first-month price at $49 for semaglutide and uses a flat-rate pricing model so dose increases do not add fees. Both disclose that compounded medications are not FDA-approved.
Choose Pallas Health if you want a clinician to pick between brand-name pens and a per-patient compounded preparation and if included provider care and brand availability are priorities.
Choose Enhance MD if your primary goal is the lowest first-month semaglutide price and a flat-rate model that keeps the same price at every dose.